SEARCH:   Advanced

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Smith, A. G. Articles by Martin, P. J. Search for Related Content PubMed PubMed Citation Articles by Smith, A. G. Articles by Martin, P. J. Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  Specific antibody-blocking activities in antilymphocyte globulin as correlates of efficacy for the treatment of aplastic anemia AG Smith, RJ O'Reilly, JA Hansen and PJ Martin Horse anti-human thoracic duct lymphocyte globulin (ATDLG) has been used successfully for the treatment of severe aplastic anemia, although not all lots have comparable efficacy. We have characterized the antibody specificities contained in one lot of Swiss ATDLG found to provide a response rate of 69% and another lot that provided only a 31% response rate. Antibody specificities were analyzed quantitatively by competitive inhibition assays with the use of a panel of fluorescein- conjugated murine monoclonal antibodies that recognize T cell antigens, common leukocyte antigens, and "la-like" antigens. Although there was wide variation in the amounts of individual antibody specificities within each lot, the effective lot of ATDLG contained an average of 2 1/2 times as much of each antibody specificity as the less effective lot. There were only two antibody specificities that differed remarkably from this pattern; and these deviations did not appear sufficient to account for the variation in ATDLG efficacy. It is possible that antibody specificities other than those tested were responsible for therapeutic efficacy. Alternatively, the data suggest that it might be possible to achieve improved results for the treatment of severe aplastic anemia with higher doses of less effective lots of ATDLG. Volume 66, Issue 3, pp. 721-723, 09/01/1985 Copyright © 1985 by The American Society of Hematology CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: R. K Barakat, J. P Schmolck, K. W Finkel, and J. R Foringer Prolonged Renal Failure Secondary to Antithymocyte Globulin Treatment in Severe Aplastic Anemia Ann. Pharmacother., May 1, 2007; 41(5): 895 - 898. [Abstract] [Full Text] [PDF]

	Copyright © 1985 by American Society of Hematology         Online ISSN: 1528-0020